Cancer Genetics Equipment For Medical Specialties
-
based in USA
The vast majority of cancer cases are detected at stage III or beyond, resulting in poor cancer survival of ~50% in the aggregate. Cancer cases are forecasted to reach 25M per year over the next two decades, causing deaths to rise to 13M per year (worldwide). Annually, the worldwide economic impact of cancer is estimated by the WHO at $1.2 trillion. ...
-
Manufactured by Tempusbased in USA
Providing risk-assessment for hereditary cancer syndromes for patients and their families. xG+ (extended hereditary cancers): Covers genes associated with multiple hereditary cancer types, including common hereditary cancers (breast, ovarian, colorectal, endometrial, prostate, pancreatic) and others (renal/urinary tract, gastric, melanoma, thyroid, endocrine, sarcomas, central nervous system, ...
-
Manufactured by Self-screen B.V.based in NETHERLANDS
The methylation assay pipeline of Self-screen has now been extended with the Precursor-M Gold assay. The newly developed Precursor-M Gold assay is currently available for Research Use Only indications. Precursor-M Gold demonstrates very good clinical performance in the detection of high grade precursor stadia and cervical cancer among HPV positive women. The assay is ready for further IVD ...
-
Manufactured by Grail, Inc.based in USA
GRAIL is poised to detect cancer early by combining high-intensity sequencing of unprecedented breadth and depth with the techniques of modern data science. Through what we believe to be one of the largest clinical study programs ever pursued in genomic medicine, GRAIL is creating vast datasets to develop evidence supporting our ...
-
Manufactured by OncoDNA S.A.based in BELGIUM
OncoSELECT: Smart liquid biopsy panels with selected key genes per tumor type. The Liquid Biopsy Solution For Disease Monitoring Or Therapeutic Decision. OncoSELECT is a fast and minimally invasive analysis of circulating tumor DNA from a blood sample for lung (NSCLC), colorectal and breast (HR+ or HER2+) cancer patients. It is the perfect solution to identify therapeutic options for cancer ...
-
Manufactured by Sysmex Partec GmbHbased in GERMANY
Highly sensitive down to 0.06 % MAF, Able to detect 6 MM with 95 % confidence across all mutations (absolute quantification), High flexibility of between 2-16 samples/run, Fast TAT (2 days), Convenient software. Plasma-SeqSensei (PSS) BC RUO Kit allows for the highly sensitive and specific detection of mutations in circulating tumour DNA (ctDNA) from the plasma of patients with breast cancer. The ...
-
Manufactured by EntroGen, Inc.based in USA
The KRAS gene encodes a small GTPase that plays a key role in transducing signals from the epidermal growth factor receptor (EGFR) to downstream effectors. KRAS mutations have been commonly found in several types of human malignancies, such as metastatic colorectal cancer (mCRC), lung adenocarcinoma and thyroid cancer. The most common mutations are found in codons 12, 13 and 61. Several studies ...
-
Manufactured by MorphoSys AGbased in GERMANY
Pelabresib (CPI-0610) is an investigational selective small-molecule designed to promote anti-tumor activity by inhibiting the function of bromodomain and extra-terminal domain (BET) proteins to decrease the expression of abnormally expressed genes in cancer. The compound has demonstrated a wide therapeutic window, with activity seen at a 48 mg dose in a lymphoma study and with a maximum ...
-
Manufactured by IMB Dx, Inc.based in SOUTH KOREA
AlphaLiquid®100 is a test that enables the detection of biomarkers which can predict the efficacy/resistance of targeted therapy for one blood test across 118 cancer-related genes. During cancer patients’ treatment journey, a simple blood draw can be used to support monitoring the treatment response and change the strategy when resistance biomarkers emerged. ...
-
by Natera, Inc.based in USA
Support treatment decisions with comprehensive tumor profiling. Gain deep insight into the tumor’s genomic alterations and oncology biomarkers with Altera. The detailed sequencing report includes FDA-approved treatments, novel treatment approaches and ongoing clinical trials targeting found mutations. Unlike any other tumor profiling assay, Altera also enables molecular residual disease ...
-
Manufactured by Manzanita Pharmaceuticals, Inc.based in USA
Nervelight™, a topical, intraoperative nerve imaging agent that is selective for at-risk nerve tissue in cancer ...
-
Manufactured by NanoIntegris Technologies, Inc.based in CANADA
The use of NanoIntegris’ HiPco within scientific research has proven quite extensive. This small-diameter SWCNT material has found to be a valuable component for applications such as cancer therapy, battery electrode conductivity, electric field enhancement, thin film transistor creation, and gas ...
-
Manufactured by GeneCentric Therapeutics, Inc.based in USA
Pancreatic Cancer is the 11th most common cancer type with an estimated 55,000 new cases in the US in 2018, according to the United States National Cancer Institute. While it represents three percent of all cancers, pancreatic cancer is one of the most lethal as it is so difficult to detect in early stages, accounting for seven percent of all cancer deaths and carrying among the lowest five ...
-
Manufactured by Qualigen Therapeutics, Inc.based in USA
Qualigen licensed the G4 selective transcription inhibitor platform from University College London (UCL) in 2022. The licensed technology comprises lead compound QN-302 (formerly SOP1812) and back-up compounds that target regulatory regions of cancer genes that down-regulate gene expression in multiple cancer pathways. Developed by Dr. Stephen Neidle and his group at UCL, the G4 binding concept ...
-
based in THAILAND
Cord blood refers to blood left in the umbilical cord after birth. Back in the day, this was generally discarded. However, because of modern advances in regenerative medical sciences, scientists have found a very useful purpose for them. The goal now is preservation or application of cord blood instead of discarding them. Why? Because it has been found to be rich in mesenchymal stem ...
-
Manufactured by D-Kimia, LLCbased in USA
The availability of a simple inexpensive test for direct detection of HCV RNA would be of substantial value in management of HCV infection. It would reduce the time and resources needed to identify patients with active infection. It would also replace the first line antibody test that cannot identify patients with acute (early) infection. Consequently, it would help enhance patients response to ...
-
based in UNITED KINGDOM
The patented Vaccitech adenovirus vectors are known as chimpanzee adenovirus Oxford 1 and 2 (ChAdOx1 and ChAdOx2), and are in the group E simian adenovirus family, similar to the widely-studied chimpanzee adenovirus 63. These viruses have been engineered to be replication deficient and can be manufactured in well-established HEK293 cell lines containing the adenoviral E1 ...
-
Manufactured by Aurora Biopharmabased in USA
The human body has a powerful immune system, and one of its white blood cells called a T-cell is like a solider capable of attacking and killing abnormal cancerous cells. However, in cancer patients, these T cells are compromised, either fail to target or recognize cancerous cells, or are too few in number to lead an strong attack. Aurora’s revolutionary CAR T Cell Therapy change a cancer ...
-
Manufactured by Wuhan HealthCare Biotechnology Co., Ltd.based in CHINA
Chromosome 6q amplifications encompassing 6q21-22 have been observed in MM including the same region as in CLL. Amplification including band 15q22 has been reported in MM. The 15q22 specific FISH probe is optimized to detect copy numbers at 15q22. The 6q21 specific DNA region is optimized to detect copy numbers at 6q21 (Cremer et al, 2005, Genes Chrom Cancer, 44; 194-203). ...
-
Manufactured by Gritstone Biobased in USA
Our second product candidate, SLATE, utilizes the same neoantigen delivery system as GRANITE but contains a fixed set of neoantigens that are shared across a subset of cancer patients rather than neoantigens unique to an individual patient, providing us with an off-the-shelf alternative to GRANITE. SLATE is being evaluated in the Phase 2 portion of a Phase I/2 clinical study in combination with ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you